Alnylam

Press Releases

Oct 15,2019
Summary ToggleAlnylam’s Distinguished Chemist Mano Manoharan Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
PDF Version
Oct 10,2019
Summary ToggleAlnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
PDF Version
Sep 26,2019
Summary ToggleAlnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference
PDF Version
Sep 16,2019
Summary ToggleAlnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
PDF Version
Sep 13,2019
Summary ToggleAlnylam Presents New Evidence Demonstrating Significant Association of V122I, a Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, with Clinical Diagnosis of Polyneuropathy
PDF Version
Sep 11,2019
Summary Toggle1,000 Alnylam Employees Across the Globe Volunteer at 5th Annual Community Service Day
PDF Version
Sep 10,2019
Summary ToggleAlnylam Presents New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
PDF Version
Sep 06,2019
Summary ToggleAlnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series
PDF Version
Sep 03,2019
Summary ToggleAlnylam Presents New Clinical Research Findings at the Second European Meeting of ATTR Amyloidosis for Doctors and Patients
PDF Version
Sep 02,2019
Summary ToggleAlnylam Pharmaceuticals Provides Perspective on Positive Complete Results from ORION-11 Phase 3 Study of Inclisiran
PDF Version
Aug 30,2019
Summary ToggleAlnylam to Webcast Presentation at 17th Annual Morgan Stanley Global Healthcare Conference
PDF Version
Aug 14,2019
Summary ToggleAlnylam to Report New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
PDF Version
Aug 13,2019
Summary ToggleAlnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
PDF Version
Aug 06,2019
Summary ToggleAlnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity
PDF Version
Aug 05,2019
Summary ToggleAlnylam Announces U.S. Food and Drug Administration (FDA) Granted Priority Review of the Givosiran New Drug Application (NDA) for the Treatment of Acute Hepatic Porphyria
PDF Version
Jul 30,2019
Summary ToggleAlnylam Pharmaceuticals and GENESIS Pharma Partner to Commercialize ONPATTRO® (patisiran) in South East Europe
PDF Version
Jul 23,2019
Summary ToggleAlnylam to Webcast Conference Call Discussing Second Quarter 2019 Financial Results
PDF Version
Jul 23,2019
Summary ToggleAlnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada
PDF Version
Jul 16,2019
Summary ToggleAlnylam and 23andMe Collaborate on +MyFamily Program to Increase Awareness of TTR-Related Hereditary Amyloidosis
PDF Version
Jul 11,2019
Summary ToggleAlnylam Pharmaceuticals Announces Transition of Chief Financial Officer
PDF Version
Displaying 1 - 20 of 1045 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More